DDInter1828 DDInter1082
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Glisoxepide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Probenecid
Tolbutamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Tolbutamide {u} (Compound) binds {v} (Gene) SLC15A1
Tolbutamide {u} (Compound) upregulates {v} (Gene) RBKS
Tolbutamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Tolbutamide {u} (Compound) downregulates {v} (Gene) SPRED2
Tolbutamide {u} (Compound) causes {v} (Side Effect) Erythema
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Tolbutamide (Compound) resembles Tolazamide (Compound)
Tolbutamide (Compound) resembles Glisoxepide (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid
Tolbutamide (Compound) treats type 2 diabetes mellitus (Disease)
Tolbutamide (Compound) binds SLC15A1 (Gene)
Tolbutamide (Compound) upregulates RBKS (Gene)
Tolbutamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Tolbutamide (Compound) downregulates SPRED2 (Gene)
Tolbutamide (Compound) causes Erythema (Side Effect)
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose